Connect with us

Hi, what are you looking for?

Economy

Pfizer to get green light for emergency use application soon

THE PHILIPPINES is expected to grant the emergency use authorization for the coronavirus vaccine developed by Pfizer, according to the chief of the local Food and Drug Administration (FDA).

The vaccine made by the US drugmaker and its German partner BioNTech SE may get the green light by Jan. 14, FDA Director-General FDA Rolando Enrique D. Domingo told an online news briefing on Wednesday.

The review had been expedited because Pfizer has obtained emergency use listing from the World Health Organization (WHO) and authorization from several countries including the US, United Kingdom, Switzerland and Singapore, he said.

“The process is fast but we are going through each step to ensure the quality, safety and efficacy of the vaccines before we give approval,” Mr. Domingo said.

Results from a late-stage vaccine trial showed that the Pfizer vaccine is 95% effective after two shots.

AstraZeneca Plc has also applied for emergency use authorization of its COVID-19 vaccine in the Philippines, Mr. Domingo.

He said the British drugmaker has a tripartite supply deal with the private sector and Philippine government. It is in talks with local governments seeking to order vaccines, he added.

“The vaccine from Oxford and AstraZeneca was already approved in the United Kingdom and India,” Mr. Domingo said. “We anticipate that they will also apply in the Philippines.”

AstraZeneca’s vaccine, which was found to be 70% effective on average after two shots, is reportedly cheaper than the Pfizer/BioNTech vaccine and does not require super cold temperatures.

Mr. Domingo said the Pfizer vaccine, “the most in-demand brand,” would most likely become available locally in the third or fourth quarter.

Meanwhile, biotechnology companies in the Philippines will seek approval for emergency use authorization for a coronavirus vaccine made by Bharat Biotech India this month, IP Biotech, Inc. said in a statement.

The FDA will get the application from IP-Biotech, Family Vaccine & Specialty Clinics and Ambica International Corp., IP Biotech said after India’s drug regulator approved the vaccine.

Bharat Biotech India’s Covaxin was developed with the Indian Council of Medical Research-National Institute of Virology.

“The indigenous, inactivated, whole virus vaccine has a standard cold chain temperature of 2-8 degrees Celsius, making it ideal for tropical countries,” IP Biotech said in the statement. — Kyle Aristophere T. Atienza

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest

Economy

WASHINGTON — US Securities and Exchange Commission (SEC) Chair Gary Gensler said that companies that help facilitate transactions in the cryptocurrency market should come...

Economy

Twitter owner and Tesla boss Elon Musk briefly lost his title as the world’s richest person on Wednesday, according to Forbes, following a steep...

Economy

BERLIN — The founder of Russia’s only LGBTQ+ museum said he was forced to close its doors on Wednesday after President Vladimir Putin signed...

Economy

Philippine lawmakers are looking to tap central bank profits to seed a proposed sovereign wealth fund, after an earlier plan to use pension funds...

Economy

Presidential elections drove this year’s Google searches in the Philippines as “Halalan 2022” topped the overall list of trending searches and “precinct finder” landed...

Economy

THE UNEMPLOYMENT RATE eased to 4.5% in October, returning to the record-low level last seen in October 2019 before the coronavirus pandemic hit, the...

You May Also Like

Investing

The minute that any question pops into your head, you can simply ask Google. No longer do we have to pour over books and...

Investing

Having a good Instagram marketing agency to back up your Instagram account is an absolute must going into the new year. With competition stronger...

Investing

Browsing history makes referring to sites and pages you’ve visited in the past seamless. It’ll help you recall what page you checked out on...

Investing

Insomnia is the most common sleep disorder in the global population. Therefore, it is a problem that many people suffer or have suffered throughout...

Disclaimer: SmartRetirementReport.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 SmartRetirementReport. All Rights Reserved.